SEC Form 4 · accession 0001140361-15-023164
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel K Spiegelman
Officer — EVP, Chief Financial Officer
Period of report
May 29, 2015
Accepted (ET)
Jun 3, 2015 · 8:27 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 29, 2015 | F | 4,305 | $125.57 | D | 37,202 | D | |
| Common StockF2,F1,F3 | May 29, 2015 | S | 1,578 | $126.1502 | D | 35,624 | D | |
| Common StockF2,F4 | Jun 1, 2015 | S | 3,945 | $124.16 | D | 31,679 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction, which should have been reported on June 2, 2015, is being reported late due to an administrative oversight.
- F2Trade made pursuant to a 10b5-1 plan executed on March 11, 2015.
- F3The price in column 4 is a weighted average price. The price actually received ranged from $125.60 to $127.78. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
- F4The price in column 4 is a weighted average price. The price actually received ranged from $123.06.60 to $124.93. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.